Molina Healthcare stock trades close to analyst target after weak Q2 2026 earnings

Molina Healthcare Inc. (ISIN US60855R1005) stock is trading close to its consensus analyst price target in late August 2026 after a weak second-quarter earnings report and cautious full-year guidance reset for 2026.

Per a late August 2026 valuation overview based on MarketBeat data, the current consensus analyst price target for Molina Healthcare stands at $202.44, while the shares most recently closed at $202.43 on August 27, 2026 and then traded intraday near $199 on August 28, 2026, indicating that the market is pricing the company almost exactly in line with the average sell-side expectation as of late August 2026.

In this context, analysts project earnings of $5.29 per share for Molina Healthcare in the 2026 fiscal year alongside a revenue outlook of $44.5 billion for 2026 and $48 billion for 2027, figures that frame the company’s current growth and profitability narrative.

Q2 2026 earnings show weaker profitability

A recent industry review of health insurance providers notes that Molina Healthcare reported second-quarter 2026 revenues of $10.87 billion, a decline of 4.8 percent compared with the same period a year earlier, highlighting a rare top-line contraction in a sector that has generally been growing.

The same quarterly snapshot indicates that Molina Healthcare generated adjusted earnings per share of $1.51 in the quarter ended June 30, 2026, down sharply from $5.48 a year earlier, underscoring the impact of higher medical costs and other pressures on profitability.

Consensus data compiled in late August 2026 show that analysts now expect the company to earn $0.73 to $0.83 per share in the current quarter ending September 30, 2026, compared with $1.84 in the prior-year quarter, a projected decline of more than 60 percent that illustrates how the market has recalibrated its near-term earnings expectations after the recent results.

Guidance reset and customer losses weigh on sentiment

The same health insurance sector review highlights that Molina Healthcare’s full-year revenue guidance for 2026 came in below analysts’ expectations, making its outlook weaker than several peers in the managed care space.

The review also notes that Molina Healthcare lost 108,000 customers over the latest period and ended the quarter with a total of 4.93 million members, a modest contraction in its enrollment base that can pressure revenue and scale benefits if not offset by pricing or mix changes.

Against this backdrop, consensus forecasts aggregated in late August 2026 point to expected earnings of $5.24 to $5.29 per share for the 2026 fiscal year and revenue of around $44.5 billion, suggesting that analysts anticipate some stabilization after the Q2 setback but still see limited upside relative to the stock’s current valuation.

Valuation stretched versus industry multiples

The late August 2026 valuation snapshot shows that Molina Healthcare stock trades at a forward price-to-earnings ratio of 24.45 based on 2026 earnings estimates of roughly $5.29 per share, a premium to an industry average multiple of 16.13 and above the company’s own five-year median valuation multiple of 14.69.

The difference between Molina Healthcare’s forward P/E of 24.45 and the industry multiple of 16.13 implies that investors are currently paying more than 50 percent higher valuation for Molina Healthcare than for the typical peer, even though its recent revenue growth and guidance have lagged the group.

With the consensus price target at $202.44 and the most recent closing price at $202.43 on August 27, 2026, the shares effectively sit on top of the average analyst target, suggesting that the market already reflects the anticipated earnings trajectory and that any further gains may depend on a clear improvement in margins, customer trends, or regulatory conditions.

Analyst consensus turns more cautious

Late August 2026 analyst data indicate that fifteen firms currently cover Molina Healthcare, with the majority of recommendations in the Hold category, a smaller number rating the shares Buy, and a few assigning Sell ratings.

These ratings combine into an average recommendation of Hold and an average 12-month price target of $202.44, reinforcing the picture of a stock that is viewed as fairly valued rather than significantly undervalued or overvalued at present.

A recent research note further shows that the consensus estimate for the current quarter’s earnings has been revised downward over the past 30 days, with the earnings-per-share estimate falling by more than 17 percent, which reflects growing concern among analysts over medical cost trends and the quality of the guidance.

Molina Healthcare’s core business model

Molina Healthcare’s core business centers on providing managed healthcare services to low-income individuals and families through government-sponsored programs in the United States.

The company operates across numerous states, focusing on Medicaid, Medicare, and Marketplace plans, where it receives per-member-per-month premiums and is responsible for managing medical costs while delivering access to essential care.

This business model can generate steady revenue streams as long as enrollment stays robust and the company accurately prices and manages the medical risk, but it is sensitive to regulatory changes, shifts in program funding, and unexpected spikes in medical utilization.

Shares trade close to key price levels

Market data snapshots for Molina Healthcare’s New York Stock Exchange listing under the ticker MOH show that the stock recently traded around $199.88 as of late August 2026, slightly below the most recent closing price of $202.43 on August 27, 2026 and very close to the consensus analyst price target of $202.44.

Technical analysis updated on August 28, 2026 indicates that Molina Healthcare shares were quoted just under $199 late in the session, with momentum and moving-average signals skewed bearish on the daily timeframe, suggesting a pause or pullback after earlier gains.

As of August 28, 2026, the shares were about 1.8 percent below that day’s earlier level and sat less than 2 percent under the consensus price target, placing the stock in a zone where any new information on earnings quality or medical trends could quickly influence whether it drifts below or reclaims the $202 area.